Equillium reports on fourth quarter and full year 2023 financial results and corporate and clinical highlights

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights. “the past year we have been focused on clinical execution that has set up the potential milestones we have in front of us in 2024,” said b.
EQ Ratings Summary
EQ Quant Ranking